Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1421146

Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for locally advanced gastric cancer

Provisionally accepted
Xiaoli Jia Xiaoli Jia Hua Fan Hua Fan Yingbin Cai Yingbin Cai *
  • Tumor Hospital of Xinjiang Medical University, Ürümqi, China

The final, formatted version of the article will be published soon.

    Background: This study aimed to evaluate the efficacy and safety of camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for locally advanced gastric cancer epically in a real-world setting.The data on patients with resectable LAGC (cT3-4aN+M0) who receive camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy from January 2020 and January 2024 was retrospectively collected. Analyses included clinicopathological features, pathological outcomes, safety, and survival data.Results: Forty-two treatment-naïve patients were enrolled. The tumor resection rate was 100.0%, and the R0 resection rate reached 95.2%. Pathological complete response (pCR) was observed in 28.6% of patients (95% CI: 14.3-42.8%), and major pathological response (MPR) was reported in 69.0% (95% CI: 53.89-82.11%). The overall response rate (ORR) stood at 54.8% (95% CI: 38.7-70.2%). Four-year diseasefree and overall survival rates were 71.4% and 81.0%, respectively. All patients experienced treatment-related adverse events (TRAEs) of any grade, with 42.9% experiencing grade ≥3 TRAEs.Conclusions: Neoadjuvant treatment involving camrelizumab, apatinib, and chemotherapy demonstrates significant efficacy and a tolerable safety profile in patients with locally advanced gastric cancer.

    Keywords: chemotherapy, LAGC, Immunotherapy, anti-angiogenic therapy, Neoadjuvant Therapy

    Received: 21 Apr 2024; Accepted: 02 Jul 2024.

    Copyright: © 2024 Jia, Fan and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yingbin Cai, Tumor Hospital of Xinjiang Medical University, Ürümqi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.